Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

An open label trial of anakinra to prevent respiratory failure in COVID-19

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Cortical signatures of precision grip force control in children, adolescents, and adults

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Identification of human glucocorticoid response markers using integrated multi-omic analysis from a randomized crossover trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Modeling transfer of vaginal microbiota from mother to infant in early life

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Host-induced spermidine production in motile Pseudomonas aeruginosa triggers phagocytic uptake

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Leukocyte Activation Profile Assessed by Raman Spectroscopy Helps Diagnosing Infection and Sepsis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Association Between Elevated suPAR, a New Biomarker of Inflammation, and Accelerated Aging

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Evdoxia Kyriazopoulou
  • Periklis Panagopoulos
  • Symeon Metallidis
  • George N Dalekos
  • Garyphallia Poulakou
  • Nikolaos Gatselis
  • Eleni Karakike
  • Maria Saridaki
  • Georgia Loli
  • Aggelos Stefos
  • Danai Prasianaki
  • Sarah Georgiadou
  • Olga Tsachouridou
  • Vasileios Petrakis
  • Konstantinos Tsiakos
  • Maria Kosmidou
  • Vassiliki Lygoura
  • Maria Dareioti
  • Haralampos Milionis
  • Ilias C Papanikolaou
  • Karolina Akinosoglou
  • Dimitra-Melia Myrodia
  • Areti Gravvani
  • Aliki Stamou
  • Theologia Gkavogianni
  • Konstantina Katrini
  • Theodoros Marantos
  • Ioannis P Trontzas
  • Konstantinos Syrigos
  • Loukas Chatzis
  • Stamatios Chatzis
  • Nikolaos Vechlidis
  • Christina Avgoustou
  • Stamatios Chalvatzis
  • Miltiades Kyprianou
  • Jos Wm van der Meer
  • Jesper Eugen-Olsen
  • Mihai G Netea
  • Evangelos J Giamarellos-Bourboulis
View graph of relations

Background: It was studied if early suPAR-guided anakinra treatment can prevent severe respiratory failure (SRF) of COVID-19.

Methods: A total of 130 patients with suPAR ≥6 ng/ml were assigned to subcutaneous anakinra 100 mg once daily for 10 days. Primary outcome was SRF incidence by day 14 defined as any respiratory ratio below 150 mmHg necessitating mechanical or non-invasive ventilation. Main secondary outcomes were 30-day mortality and inflammatory mediators; 28-day WHO-CPS was explored. Propensity-matched standard-of care comparators were studied.

Results: 22.3% with anakinra treatment and 59.2% comparators (hazard ratio, 0.30; 95% CI, 0.20-0.46) progressed into SRF; 30-day mortality was 11.5% and 22.3% respectively (hazard ratio 0.49; 95% CI 0.25-0.97). Anakinra was associated with decrease in circulating interleukin (IL)-6, sCD163 and sIL2-R; IL-10/IL-6 ratio on day 7 was inversely associated with SOFA score; patients were allocated to less severe WHO-CPS strata.

Conclusions: Early suPAR-guided anakinra decreased SRF and restored the pro-/anti-inflammatory balance.

Funding: This study was funded by the Hellenic Institute for the Study of Sepsis, Technomar Shipping Inc, Swedish Orphan Biovitrum, and the Horizon 2020 Framework Programme.

Clinical trial number: NCT04357366.

Original languageEnglish
Article numbere66125
JournaleLife
Volume10
Pages (from-to)1-21
Number of pages21
ISSN2050-084X
DOIs
Publication statusPublished - 8 Mar 2021

    Research areas

  • Anakinra, COVID-19, Interleukin-10, Severe respiratory failure, SuPAR

ID: 64083353